Quest for the right Drug
זובירקס IV ZOVIRAX I.V. (ACICLOVIR)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה לאינפוזיה : POWDER FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmaceutical particulars : מידע רוקחי
6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium hydroxide (used to adjust pH) 6.2 Incompatibilities The reconstituted concentrate and diluted solution for infusion must not be mixed with other medicinal products except those mentioned in Section 6.6. 6.3 Shelf life The expiry date of the product is indicated on the packaging materials. 6.4 Special precautions for storage Store below 25oC 6.5 Nature and contents of container Type I glass vials closed with butyl or bromobutyl rubber stoppers secured by aluminium collars. 6.6 Special precautions for disposal and other handling Reconstitution: Zovirax I.V. should be reconstituted using the following volumes of either Water for Injections BP or Sodium Chloride Intravenous Injection BP (0.9% w/v) to provide a solution containing 25 mg aciclovir per ml: Formulation Volume of fluid for reconstitution 250 mg vial 10 ml From the calculated dose, determine the appropriate number and strength of vials to be used. To reconstitute each vial add the recommended volume of infusion fluid and shake gently until the contents of the vial have dissolved completely. Administration: The required dose of Zovirax I.V. should be administered by slow intravenous infusion over a one-hour period. After reconstitution Zovirax I.V. may be administered by a controlled-rate infusion pump. Alternatively, the reconstituted solution may be further diluted to give an aciclovir concentration of not greater than 5 mg/ml (0.5% w/v) for administration by infusion: Add the required volume of reconstituted solution to the chosen infusion solution, as recommended below, and shake well to ensure adequate mixing occurs. For children and neonates, where it is advisable to keep the volume of infusion fluid to a minimum, it is recommended that dilution is on the basis of 4 ml reconstituted solution (100 mg aciclovir) added to 20 ml of infusion fluid. For adults, it is recommended that infusion bags containing 100 ml of infusion fluid are used, even when this would give an aciclovir concentration substantially below 0.5% w/v. Thus one 100 ml infusion bag may be used for any dose between 250 mg and 500 mg aciclovir (10 and 20 ml of reconstituted solution) but a second bag must be used for doses between 500 mg and 1000 mg. When diluted in accordance with the recommended schedules, Zovirax I.V. is known to be compatible with the following infusion fluids and stable for up to 12 hours at room temperature (15°C to 25°C): Sodium Chloride Intravenous Infusion BP (0.45% and 0.9% w/v) Sodium Chloride (0.18% w/v) and Glucose (4% w/v) Intravenous Infusion BP Sodium Chloride (0.45% w/v) and Glucose (2.5% w/v) Intravenous Infusion BP Compound Sodium Lactate Intravenous Infusion BP (Hartmann's Solution). Zovirax I.V. when diluted in accordance with the above schedule will give an aciclovir concentration not greater than 0.5% w/v. Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under full aseptic conditions, immediately before use, and any unused solution discarded. Should any visible turbidity or crystallisation appear in the solution before or during infusion, the preparation should be discarded.
שימוש לפי פנקס קופ''ח כללית 1994
Viral infections with herpes simplex 1 & 2, herpes zoster & varicella zoster. Treatment of herpes simplex encephalitis, genital herpes, herpes simplex keratitis, severe labial herpes, herpes zoster. Varicella pneumonia in all immunocompromised and immunocompetent patients with severe manifestations of the disease. prophylaxis of recurrent mucosal and cutaneous herpes simplex or labialis (severe). patients with bone marrow transplant. יירשם ע"י רופא מומחה למחלות זיהומיות או רופא מומחה שהורשה ע"י הנהלת המחוז
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף